-13.3%
BKNG vs MRNA
+909.7%
-923.0%
-32.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | -6.5% | +5.2% | -1.2% |
| 7D | +12.2% | +8.4% | +3.8% | +12.0% |
| 30D | +7.0% | +28.8% | -21.8% | +6.4% |
| 3M | -18.3% | +329.2% | -347.5% | -22.3% |
| 6M | +1.1% | +416.9% | -415.8% | -5.2% |
| YTD | -20.7% | +718.8% | -739.5% | -30.4% |
| 1Y | -13.3% | +924.9% | -938.2% | -29.5% |
| All | -13.3% | +909.7% | -923.0% | -29.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling